PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1514987
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1514987
Mutation Detection Kits In Genome Editing Market size was valued at USD 412.14 Million in 2023, expanding at a CAGR of 16.5% from 2024 to 2032.
Mutation detection kits in genome editing play a pivotal role in identifying and analyzing genetic mutations post gene editing procedures. Leveraging techniques like PCR, CRISPR-Cas9, and next-generation sequencing, these kits detect precise changes in DNA sequences with utmost accuracy. Vital for validating genome editing success, ensuring gene modification accuracy, and pinpointing off-target effects, they find extensive applications in research, clinical diagnostics, and biotechnology. By enabling progress in genetic engineering, personalized medicine, and genetic disease research, these kits significantly advance molecular biology, underscoring their importance in scientific and medical communities.
Mutation Detection Kits In Genome Editing Market- Market Dynamics
Widespread adoption of genome editing techniques and increased investment to propel market demand
The growth of the Mutation Detection Kits market for Genome Editing is primarily fueled by the widespread adoption of genome editing techniques and increased investment in mutation detection kit development. These advancements have accelerated the adoption of genome editing methodologies across various research and clinical applications, including pharmacogenetics, disease treatment, and reverse genetics studies. The detection of polymorphisms and unknown mutations in genome sequences is critical for such endeavors, driving the demand for mutation detection kits. The introduction of novel methods like CRISPR-EXPAR, utilizing CRISPR-Cas9 and Exponential Amplification Reaction (EXPAR), further expands the capabilities of mutation detection, attracting more players to gene manipulation technologies and propelling market growth.
Mutation Detection Kits In Genome Editing Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 16.5% over the forecast period (2024-2032)
Based on Technology segmentation, CRISPR/Cas9 technology was predicted to show maximum market share in the year 2023
Based on End User segmentation, Academic and government research institutes were the leading type in 2023
Based on region, North America was the leading revenue generator in 2023
The Global Mutation Detection Kits In Genome Editing Market is segmented based on Technology, End User, and Region.
The market is divided into five categories based on Technology: CRISPR/Cas9, ZFN, TALENs/MegaTALs, Meganucleases and Others. In 2023, the market was dominated by CRISPR/Cas9 technology, which has fundamentally transformed genetic testing and medical diagnostics. The segment's growth is driven by the increasing adoption of gene therapy and the plethora of therapies undergoing clinical trials. Additionally, the continuous development of new tools based on CRISPR technology further supplements market expansion.
The market is divided into two three categories based on End User: Biotechnology and Pharmaceutical Companies, Academic & Government Research Institutes and Contract Research Organizations. Academic and government research institutes emerged as the frontrunners in the market, particularly in 2023. This dominance is fueled by ongoing clinical trials, a growing preference for personalized medicine, and intensified R&D endeavors in clinical diagnostics. The outbreak of COVID-19 has acted as a catalyst for the market's expansion, accentuating the importance of mutation detection kits in various research applications.
Mutation Detection Kits In Genome Editing Market- Geographical Insights
In terms of location, this market reaches across North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Individual countries within these regions create further market breakdowns. North America claimed the lion's share of the market revenue in 2023. This leadership position can be attributed to several factors, including the substantial presence of market players, significant R&D investments, and the continuous advancements in technology led by key industry players. Furthermore, the supportive regulatory landscape in the region is anticipated to drive further adoption of mutation detection kits. For example, Health Canada's endorsement of the safety of gene-editing technology in crops is expected to encourage Canadian farmers to adopt gene-edited crops, thus stimulating research on transgene plants.
In the Mutation Detection Kits market for Genome Editing, key players adopt various strategic initiatives like partnerships, product diversification, and technological advancements to stay competitive. Collaborations with genome editing technology developers and research institutions enable access to cutting-edge expertise, fostering the development of highly sensitive mutation detection kits. These partnerships drive innovation in methodologies like next-generation sequencing, enhancing detection efficiency for genetic modifications induced by tools like CRISPR-Cas9. Product diversification ensures a comprehensive range of kits tailored to diverse genome editing applications. Investments in R&D focus on improving detection sensitivity and specificity, addressing evolving research and therapeutic needs. Through such strategies, companies maintain market leadership, drive innovation, and contribute to precision medicine and gene therapy advancements.
In April 2021, A study by a collaborative team from UC Berkeley, Keck Graduate Institute (KGI), and Vilnius University yielded a novel handheld device utilizing CRISPR technology. This innovative device integrates CRISPR with graphene transistors, enabling rapid detection of specific genetic mutations. Dubbed CRISPR-Chip, it has the potential to streamline genetic disease diagnosis and assess the accuracy of genome-editing techniques.
GLOBAL MUTATION DETECTION KITS IN GENOME EDITING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHT
Thermo Fisher Scientific
Takara Bio Inc.
Integrated DNA Technologies, Inc.
Lucigen
Promega Corporation
GenScript
Synthego
New England Biolabs
Applied Biological Materials, Inc. (ABM)
Bio-Rad Laboratories
AddGene
Biovision Inc.
Others